For EVERY treatment success claimed by embryo stem cell proponents, there is an ethical therapy either available or in the pipeline that is much more promising.

Hyped Embryonic Stem Cell “treatments:”
Mixed results in animal models.

More successful, ethical alternative:
Treating HUMANS today.

Parkinson’s Disease

In 2004, human embryonic stem cells were differentiated into dopamine-producing neurons and transplanted into a rat model of Parkinson’s. This treatment only “slightly” improved symptoms in rats (about 25%).  

In a similar study in 2002, one-fifth (20%) of the rats died of brain tumors caused by the embryonic stem cells.  Hardly a successful treatment when 20% of subjects are killed in the process.

 

Parkinson’s patient treated with his own adult stem cells continues to exhibit relief from 80% of his symptoms more than 6 years after his surgery.  A Phase I human clinical trial using this therapy is currently underway. 

A Phase II clinical trial is underway in human patients using a growth factor to stop the destruction of neurons in the brain.  In the Phase I trial, patients showed 60% improvement in their symptoms.

Spinal Cord Injury

In 2002, researchers reported using human EScells to treat SCI in rats.  This result has yet to be published, yet Geron Corp. continues to insist that human clinical trials will begin “soon.”
 

 

Dr. Carlos Lima has treated over 34 patients with spinal cord injury in Portugal with their own adult stem cells.  

Umbilical cord blood cells were used to treat a South Korean woman who had been paralyzed for 19 years. She can now walk with braces.

Juvenile Diabetes

Several reports have claimed to turn human EScells into insulin-producing cells.  In each case, the insulin levels produced have been very low, and other researchers, including Dr. Doug Melton from Harvard, have demonstrated that these cells were likely not producing insulin at all.
 

Dr. Denise Faustman, a leading diabetes researcher from Harvard, has completely reversed end-stage Juvenile diabetes in mice and has FDA approval to begin a human clinical trial.

 

Published treatments in HUMAN PATIENTS

Embryonic

Adult

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
1   Brain Cancer
2   Retinoblastoma
3   Ovarian Cancer
4   Merkel Cell Cancer
5   Testicular Cancer
6   Lymphoma
7   Acute Lymphoblastic Leukemia
8   Acute Myelogenous Leukemia
9   Chronic Myelogenous Leukemia
10  Juvenile Myelomonocytic Leukemia
11  Angioimmunoblastic     Lymphadenopathy  with Dysproteinemia
12  Multiple Myeloma
13  Myelodysplasia
14  Breast Cancer
15  Neuroblastoma
16  Non-Hodgkin's Lymphoma
17  Hodgkin's Lymphoma
18  Renal Cell Carcinoma
19  Various Solid Tumors
20  Soft Tissue Sarcoma
21  Scleromyxedema
22  Multiple Sclerosis
23  Crohn's Disease
24  Rheumatoid Arthritis
25  Juvenile Arthritis
26  Systemic Lupus
27   Polychondritis
28   Systemic Vasculitis
29   Sjogren's Syndrome
30   Behcet's Disease
31   Myasthenia Gravis
32   Red Cell Aplasia		 33 Autoimmune Cytopenia
34 X-Linked Lymphoproliferative Syndrome
35 X-Linked Hyperimmunoglobuline-M Syndrome
36 Severe Combined Immunodeficiency Syndrome-X1
37 Sickle Cell Anemia
38 Sideroblastic Anemia
39 Waldenstrom's Macroglobulinemia
40  Aplastic Anemia
41  Amegakaryocytic Thrombocytopenia
42  Chronic Epstein-Barr Infection
43  Fanconi's Anemia
44  Diamond Blackfan Anemia
45  Thalassemia Major
46  Stroke
47  Osteogenesis Imperfecta
48  Sandhoff Disease
49  Corneal Degeneration
50  Hemophagocytic Lymphohistiocytosis
51  Primary Amyloidosis
52  Limb Gangrene
53  Surface Wound Healing
54  Heart Damage
55  Parkinson's Disease
56  Spinal Cord Injury
57  Scleroderma
58  Hurler's Syndrome 

 

 

 

0

58